These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 24469917)

  • 1. CD4+ T cells in HIV infection show increased levels of expression of a receptor for vasoactive intestinal peptide, VPAC2.
    Ipp H; Nkambule BB; Reid TD; de Swardt D; Bekker LG; Glashoff RH
    Immunol Res; 2014 Oct; 60(1):11-5. PubMed ID: 24469917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit antigen-induced apoptosis of mature T lymphocytes by inhibiting Fas ligand expression.
    Delgado M; Ganea D
    J Immunol; 2000 Feb; 164(3):1200-10. PubMed ID: 10640731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective gene expression and activation-dependent regulation of vasoactive intestinal peptide receptor type 1 and type 2 in human T cells.
    Lara-Marquez M; O'Dorisio M; O'Dorisio T; Shah M; Karacay B
    J Immunol; 2001 Feb; 166(4):2522-30. PubMed ID: 11160313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit T cell-mediated cytotoxicity by inhibiting Fas ligand expression.
    Delgado M; Ganea D
    J Immunol; 2000 Jul; 165(1):114-23. PubMed ID: 10861043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Altered expression of vasoactive intestinal peptide receptors in T lymphocytes and aberrant Th1 immunity in multiple sclerosis.
    Sun W; Hong J; Zang YC; Liu X; Zhang JZ
    Int Immunol; 2006 Dec; 18(12):1691-700. PubMed ID: 17077178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vasoactive intestinal peptide (VIP) receptor type 2 (VPAC2) is the predominant receptor expressed in human thymocytes.
    Lara-Marquez ML; O'Dorisio MS; Karacay B
    Ann N Y Acad Sci; 2000; 921():45-54. PubMed ID: 11193874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A cloned frog vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptor exhibits pharmacological and tissue distribution characteristics of both VPAC1 and VPAC2 receptors in mammals.
    Alexandre D; Anouar Y; Jegou S; Fournier A; Vaudry H
    Endocrinology; 1999 Mar; 140(3):1285-93. PubMed ID: 10067855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radical reversal of vasoactive intestinal peptide (VIP) receptors during early lymphopoiesis.
    Vomhof-DeKrey EE; Sandy AR; Failing JJ; Hermann RJ; Hoselton SA; Schuh JM; Weldon AJ; Payne KJ; Dorsam GP
    Peptides; 2011 Oct; 32(10):2058-66. PubMed ID: 21878358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A lymphocyte-generated fragment of vasoactive intestinal peptide with VPAC1 agonist activity and VPAC2 antagonist effects.
    Summers MA; O'Dorisio MS; Cox MO; Lara-Marquez M; Goetzl EJ
    J Pharmacol Exp Ther; 2003 Aug; 306(2):638-45. PubMed ID: 12750439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vasoactive intestinal peptide (VIP) receptor expression in monocyte-derived macrophages from COPD patients.
    Burian B; Storka A; Marzluf BA; Yen YC; Lambers C; Robibaro B; Vonbank K; Mosgoeller W; Petkov V
    Peptides; 2010 Apr; 31(4):603-8. PubMed ID: 20026142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allergic diathesis in transgenic mice with constitutive T cell expression of inducible vasoactive intestinal peptide receptor.
    Voice JK; Dorsam G; Lee H; Kong Y; Goetzl EJ
    FASEB J; 2001 Nov; 15(13):2489-96. PubMed ID: 11689474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Roles of vasoactive intestinal peptide (VIP) in the expression of different immune phenotypes by wild-type mice and T cell-targeted type II VIP receptor transgenic mice.
    Voice JK; Grinninger C; Kong Y; Bangale Y; Paul S; Goetzl EJ
    J Immunol; 2003 Jan; 170(1):308-14. PubMed ID: 12496414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. VPAC2-R mediates the lipolytic effects of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide in primary rat adipocytes.
    Akesson L; Ahrén B; Edgren G; Degerman E
    Endocrinology; 2005 Feb; 146(2):744-50. PubMed ID: 15514088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alterations in the relative abundance of the vasoactive intestinal peptide receptors (VPAC1 and VPAC2) and functions in uterine contractility during inflammation.
    Palus K; Całka J; Jana B
    Anim Reprod Sci; 2021 Feb; 225():106680. PubMed ID: 33388613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. VIP enhances synaptic transmission to hippocampal CA1 pyramidal cells through activation of both VPAC1 and VPAC2 receptors.
    Cunha-Reis D; Ribeiro JA; Sebastião AM
    Brain Res; 2005 Jul; 1049(1):52-60. PubMed ID: 15935995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. VIP and PACAP inhibit activation induced apoptosis in T lymphocytes.
    Delgado M; Ganea D
    Ann N Y Acad Sci; 2000; 921():55-67. PubMed ID: 11193880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. VIP attenuation of the severity of experimental pancreatitis is due to VPAC1 receptor-mediated inhibition of cytokine production.
    Kojima M; Ito T; Oono T; Hisano T; Igarashi H; Arita Y; Kawabe K; Coy DH; Jensen RT; Nawata H
    Pancreas; 2005 Jan; 30(1):62-70. PubMed ID: 15632701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pituitary adenylate cyclase-activating polypeptide and PACAP receptor expression and function in the rat adrenal gland.
    Mazzocchi G; Malendowicz LK; Neri G; Andreis PG; Ziolkowska A; Gottardo L; Nowak KW; Nussdorfer GG
    Int J Mol Med; 2002 Mar; 9(3):233-43. PubMed ID: 11836629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. VPAC1 (vasoactive intestinal peptide (VIP) receptor type 1) G protein-coupled receptor mediation of VIP enhancement of murine experimental colitis.
    Yadav M; Huang MC; Goetzl EJ
    Cell Immunol; 2011; 267(2):124-32. PubMed ID: 21295288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential upregulation of CD38 on different T-cell subsets may influence the ability to reconstitute CD4+ T cells under successful highly active antiretroviral therapy.
    Benito JM; López M; Lozano S; Ballesteros C; Martinez P; González-Lahoz J; Soriano V
    J Acquir Immune Defic Syndr; 2005 Apr; 38(4):373-81. PubMed ID: 15764953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.